Researchers at MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays, and improved patient satisfaction.
Antonio C. Wolff, chair of the Breast Cancer Committee for the ECOG-ACRIN Cancer Research Group, will co-lead the Breast Cancer Steering Committee for NCI. He began the three-year term on April 1.
Study finds TNBC tumors with an increase in immune cells have lower risk of recurrence after surgery
A multicenter, international study suggests that people who have early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes within their tumors may have a lower risk of recurrence and better survival rates, even when not treated with chemotherapy.
When Stephanie Graff was a breast oncology fellow in 2010, one of her patients brought a marked up copy of “Dr. Susan Love’s Breast Book” to an appointment.
A novel treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a phase III trial co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.
Research evaluating data from the American College of Surgeons National Cancer Database (NCDB) showed a 15-20% decrease in newly diagnosed breast cancer cases reported to Commission on Cancer sites in 2020, compared to 2019.
University of Cincinnati Cancer Center researchers in the lab of Jun-Lin Guan have identified a protein that helps prevent metastasis of HER2-positive breast cancer. About 20% of breast cancer patients are HER2-positive, and these cancers tend to be more aggressive than other types.
The 2023 San Antonio Breast Cancer Symposium (SABCS), held Dec. 5-9 at the city’s Henry B. Gonzalez Convention Center, had a record-setting attendance with 10,874 registered attendees from 102 countries.
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.
Rice University researchers in the lab of chemist Han Xiao have identified a promising new immunological pathway to treat stubborn bone tumors, one of most prevalent forms of metastases in breast cancer patients.